Thymoma

Observed

← altered in cohorts of

PRSS1

48 / 124 cases (39 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PRSS2

45 / 124 cases (36 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

MTRNR2L6

44 / 124 cases (35 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FOXD4L5

32 / 124 cases (26 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ANKRD20A3P

30 / 124 cases (24 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CBWD5

30 / 124 cases (24 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ANKRD20A4P

29 / 124 cases (23 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FOXD4L4

29 / 124 cases (23 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ZNF658

28 / 124 cases (23 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ANKRD20A1

27 / 124 cases (22 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CBWD3

27 / 124 cases (22 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FOXD4L3

27 / 124 cases (22 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

SPATA31A3

27 / 124 cases (22 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR11H12

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T10

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T11

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T2

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T29

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T3

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T34

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T35

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T5

26 / 124 cases (21 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FMN2

25 / 124 cases (20 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR14I1

25 / 124 cases (20 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2G6

25 / 124 cases (20 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T27

25 / 124 cases (20 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PRG4

25 / 124 cases (20 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

RYR2

25 / 124 cases (20 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

TPR

25 / 124 cases (20 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ADORA1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

BLZF1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CACNA1E

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CENPF

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CHRM3

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CNTN2

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CNTNAP3C

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

COLGALT2

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

CYB5R1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

DCAF6

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FAM72D

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FCGR2B

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FCGR3A

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

FCGR3B

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

GPR89A

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

H3-2

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

H3-3A

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

HMCN1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

HSPA6

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

KCNT2

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

KIF14

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

LIN9

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

LYPD8

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

NBPF15

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

NBPF20

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OBSCN

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ODR4

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR14A16

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T6

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PDC

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PDZK1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PIK3C2B

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PPIAL4D

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PPIAL4F

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PROX1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

RAB3GAP2

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

SFT2D2

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

SPATA31A5

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

SPATA31A7

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

SPTA1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

SRGAP2B

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

TP53BP2

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

WASHC1

24 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ACTN2

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ANGPTL1

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ELF3

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ENAH

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

EXOC8

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

INTS7

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

KIF21B

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

LMOD1

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

MYOG

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2G2

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

OR2T12

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PEX11B

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

PLEKHA6

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

RGS18

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

RGS8

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

RPS6KC1

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

RRP15

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

SPATA17

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

TSEN15

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

← altered in cohorts of

ZNF648

23 / 124 cases (19 %) · ssm · TCGA-THYM

—

Observed

Thymoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 22show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Thymoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall_molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall_molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall_molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Amrubicinsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Avelumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Belinostatsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bosutinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Buparlisibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Celecoxibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall_molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinibsmall_molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall_molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Thymoma	1	Observed	clinicaltrials	graph →

Thymoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 22show all (up to 200)

→ investigated in trials for

Pembrolizumabmonoclonal_antibody

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenvatinibsmall_molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall_molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall_molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Amrubicinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avelumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Belinostatsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bosutinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Buparlisibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Celecoxibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall_molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinibsmall_molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall_molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Thymoma studied in …STUDIED_INderived10 of 79show all (up to 200)
→ studied in	NCT01242072Phase 1 · completed Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03076554Phase 2 · active not recruiting A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03968315NA · active not recruiting An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05150210NA · active not recruiting SP Thoracic IDE Study · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06248515Phase 2 · recruiting A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01950572recruiting Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04417660Phase 2 · active not recruiting Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma · condition mapped CURATED_BROADER · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05104736Phase 2 · recruiting PT-112 in Subjects With Thymoma and Thymic Carcinoma · condition mapped CURATED_BROADER · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01025089Phase 2 · active not recruiting Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03295227Phase 1 · recruiting Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer · condition mapped CURATED_BROADER · 79 trials mapped (23 active)	—	—	Thymoma	1	Observed	clinicaltrials	graph →

Thymoma studied in …STUDIED_INderived10 of 79show all (up to 200)

→ studied in

NCT01242072Phase 1 · completed

Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT03076554Phase 2 · active not recruiting

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT03968315NA · active not recruiting

An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT05150210NA · active not recruiting

SP Thoracic IDE Study · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT06248515Phase 2 · recruiting

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT01950572recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT04417660Phase 2 · active not recruiting

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma · condition mapped CURATED_BROADER · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT05104736Phase 2 · recruiting

PT-112 in Subjects With Thymoma and Thymic Carcinoma · condition mapped CURATED_BROADER · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT01025089Phase 2 · active not recruiting

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma · condition mapped ONTOLOGY_EXACT · 79 trials mapped (23 active)

—

Observed

→ studied in

NCT03295227Phase 1 · recruiting

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer · condition mapped CURATED_BROADER · 79 trials mapped (23 active)

—

Observed